Contraline secured $92.5 million to advance two male contraceptive candidates, including a once-daily topical gel and an implantable option. The funding is intended to move both programs forward as Contraline works toward clinical development milestones. The financing matters in reproductive health innovation because male contraception has been underdeveloped relative to female options, and competing approaches require clear differentiation on efficacy, usability, and tolerability. Contraline’s dual-asset strategy aims to hedge format risk while building a pipeline portfolio. The round adds capital to a focused segment with high unmet need and long timelines, where regulatory clarity and trial design quality can determine whether novel mechanisms convert into viable products.